After eight daunting months of battling COVID-19, there may be some light at the end of the tunnel as two potential vaccine candidates recently announced promising test results. 

Vaccines from Pfizer and Moderna are similar in that they both use emerging technology called messenger ribonucleic acid (mRNA) to reach nearly 95 percent efficacy. Typically, scientists create vaccines by using live or inactivated virus cells, which puts the actual disease into a person’s body. However, with mRNA technology, Pfizer and Moderna were able to avoid that. MRNA carries coded instructions that tell cells what defenses are necessary by appearing as a threat. 

Of Course, There's a Catch

The use of the molecule is groundbreaking for a number of reasons. One is the speed at which the vaccines were developed. The other is that the use of mRNA means the vaccines contain no infectious COVID-19 properties that could get patients sick. 

However, there is a drawback to the vaccines: they have to be stored in brutally cold temperatures.

Under normal circumstances, vaccines can survive when stored at around 40 degrees Fahrenheit, but for Moderna, the vials must be stored at -4 degrees.

For Pfizer's vaccine, the threshold for keeping an effective dose is even steeper at a staggering -94 degrees. The icy temperatures are necessary to keep the mRNA molecule intact, otherwise it “begins to fall apart and twist around in ways so that it doesn’t become effective,” a representative for the pharmaceutical giant told Cheddar.

Vaccine Storage & Distribution Roadblock

With the need for cold storage comes the obstacle of how to pull off widespread distribution. Most hospitals in the U.S. do not house facilities that meet the requirements to store either the Moderna or Pfizer vaccines for extended periods. Both vaccines are able to survive in typical storing temperatures of 35 to 46 degrees, but their shelf lives are limited that way.

For Pfizer, the vaccine would no longer be effective after five days in normal storage temperatures. Moderna, meanwhile, shows more promise when it comes to effective distribution as it’s vaccines appear to remain effective for a month while stored 35 degrees.

Pfizer has come up with a plan to ship its vaccine in boxes filled with dry ice. The vials will remain protected for up to 15 days -- but the container can only be opened up to two times per day. 

This could be a logistical nightmare for parts of the world that don't have sufficient equipment - or enough dry ice - to keep the vaccines. Even in rural America, many hospitals don't have freezers that can keep doses cold enough, particularly for the Pfizer vaccine.  

Getting Vaccinated

So what does this mean for you? Once the FDA approves emergency use authorization of either one or both of the vaccines, it looks like they will likely be distributed first among populations that need it the most: frontline healthcare workers, the elderly, and those suffering from underlying health conditions. 

Like several existing vaccinations for other conditions, both Pfizer and Moderna require two rounds of treatment in order for the body to build up complete immunity. For those receiving the Pfizer vaccine, patients will need to return for a second dose after three weeks and for those getting the Moderna vaccine, they'll have to go back for round two after four weeks. 

Video produced by Ali Larkin. Article written by Lawrence Banton.

Share:
More In Science
Scientists Sue to Protect Utah National Monuments
Sophie Bushwick, senior editor for Popular Science, discusses the Trump administration's recent announcement to scale back the size of two national monuments in Utah, which are home to over 400 research sites employing 2,000 scientists.
Kimbal Musk is Transforming Food in America
Kimbal Musk is on a mission to base the American restaurant and food system on clean farming and eating. He is transforming food the same way his brother, Elon, is transforming electric cars and space travel.
Why It's Hard to Get Those ZZZ's
Can you remember the last time you had a good night's sleep? Many people go weeks without sleeping through the entire night. Marina Khidekel, Senior Deputy Editor at Women's Health, joins Cheddar to talk about its latest sleep study in partnership with Thrive Global and the American Sleep Association.
Boeing Challenges SpaceX to Mars
Boeing's Chief Executive has once again told the public his company will beat Elon Musk's SpaceX in its mission to Mars. Will Goodman, Managing Editor at Rockets are Cool, joins Cheddar to discuss the competition between the two aviation companies.
Revolutionizing Healthcare with Early Disease Detection
Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare.
Increasing Access to Therapy Through A.I.
Woebot is an A.I. chat robot on Facebook that is increasing access to therapy. The new chatbot is a digital alternative to going to see a therapist, and is currently free.
The Potential of an Elon Musk Mega Company
Could a merger of SpaceX and Tesla be in Elon Musk's future? An analyst at Morgan Stanley seems to think so, writing a note that lays out several reasons why, he thinks, a full partnership between the two companies could happen. Linda Lacina, Managing Editor at Entrepreneur joins Cheddar to discuss the news.
Kelly Noonan Gores Focuses on the Mind-Body Connection in “Heal” Documentary
Kelly Noonan Gores takes viewers inside the connection between our bodies and minds with her new critically-acclaimed documentary “Heal.” She sits down with Alyssa Julya Smith at Cheddar’s WeWork studio in Los Angeles to discuss the spiritual journey people take to become healthy, and to rid the body of stressors that can cause illness.
Load More